Gilead Sciences, Inc. (Nasdaq: GILD) has reported positive Phase 3 IDEAL results showing that 75.4% of patients receiving Livdelzi (seladelpar) achieved the study’s prespecified alkaline phosphatase normalisation endpoint at Week 52, compared with 16.1% receiving placebo. Announced on 5 November 2026, the findings provide randomised clinical evidence supporting biochemical improvement in adults with primary biliary cholangitis whose alkaline phosphatase levels remained above normal but below the threshold traditionally used to enrol patients in pivotal second-line treatment trials.
The study involved 96 adults and examined a population that has been relatively underrepresented in earlier randomised investigations of second-line PBC therapies. Unlike previous trials focused largely on patients with more pronounced biochemical abnormalities, IDEAL evaluated whether Livdelzi could help patients with baseline alkaline phosphatase levels below 1.67 times the upper limit of normal achieve a stricter biochemical treatment goal.
The results strengthen the evidence supporting seladelpar’s ability to improve an important marker of PBC disease activity. However, the findings do not establish that the medicine prevents liver failure, reduces mortality or delays transplantation, and they do not represent a new FDA approval. Gilead Sciences plans to discuss the evidence with global regulatory authorities while continuing its broader clinical and commercial programme.
What does the Phase 3 IDEAL trial reveal about Livdelzi’s ability to normalise alkaline phosphatase?
IDEAL was a randomised, double-blind, placebo-controlled Phase 3 study evaluating Livdelzi in adults with primary biliary cholangitis and alkaline phosphatase levels above the upper limit of normal but below 1.67 times that threshold.
Participants had persistent biochemical elevation despite receiving ursodeoxycholic acid for an appropriate treatment period or were unable to tolerate ursodeoxycholic acid. The trial enrolled 96 adults aged 18 to 75 years.
The primary endpoint was a composite assessment requiring two conditions at Week 52: alkaline phosphatase at or below the upper limit of normal and a reduction of at least 15% from baseline.
The use of a composite endpoint is important because reaching a value within the normal laboratory range alone might not reflect a substantial change for an individual whose baseline measurement was only slightly elevated.
Requiring a reduction from baseline therefore creates a more demanding assessment of treatment response in patients whose initial alkaline phosphatase levels are relatively close to normal.
According to Gilead Sciences, 49 of 65 patients receiving Livdelzi met the primary endpoint, representing 75.4% of the treatment group. Among 31 placebo recipients, five achieved the same endpoint, equivalent to 16.1%.
The absolute difference between the groups was 59.3 percentage points, a substantial effect on the prespecified biochemical endpoint.
The company reported that the difference was statistically significant, supporting the conclusion that treatment produced a greater likelihood of achieving the defined alkaline phosphatase response than placebo in the studied population.
The response also emerged relatively early. After one month, 52.3% of Livdelzi recipients had achieved the relevant normalisation response compared with 6.5% in the placebo group.
This early separation suggests that the biochemical effect can become apparent within weeks of treatment initiation. However, the long-term clinical implications of an early laboratory response still require evidence concerning disease progression and patient outcomes.
The 52-week findings demonstrate sustained group-level biochemical activity over the study period. They do not establish how long individual responses persist after treatment discontinuation or whether patients experience equivalent long-term benefits.
Why does IDEAL focus on PBC patients with alkaline phosphatase below 1.67 times normal?
Primary biliary cholangitis is a chronic autoimmune disease that damages the small bile ducts within the liver. Progressive bile duct injury can produce cholestasis, inflammation and fibrosis, potentially leading to cirrhosis and liver failure.
Ursodeoxycholic acid remains the established first-line treatment. However, a proportion of patients experience an inadequate biochemical response or cannot tolerate the medicine.
Historically, many pivotal clinical trials evaluating second-line PBC therapies have required alkaline phosphatase levels above 1.67 times the upper limit of normal. This threshold helped identify patients with more pronounced biochemical abnormalities and provided a relatively consistent basis for comparing treatment responses.
Patients with alkaline phosphatase levels above normal but below that threshold have often been excluded from these studies. Consequently, clinicians have had less controlled evidence concerning the benefits of additional treatment in this population.
IDEAL specifically addresses that gap by evaluating whether further alkaline phosphatase reduction is achievable in patients with more modest baseline elevations.
This is clinically relevant because elevated alkaline phosphatase has been associated with long-term PBC outcomes, including the risk of disease progression. The relationship between liver biochemistry and prognosis has encouraged greater interest in achieving lower treatment targets.
However, an elevated alkaline phosphatase value does not independently determine every patient’s risk. Bilirubin, liver stiffness, fibrosis, symptoms and other clinical characteristics also contribute to prognosis.
The IDEAL findings therefore support considering biochemical response within a more comprehensive risk assessment rather than establishing that every patient with a mildly elevated alkaline phosphatase level requires an additional medicine.
Cynthia Levy of the University of Miami Miller School of Medicine, who commented on the results, emphasised the importance of using the findings to inform individualised treatment discussions incorporating disease progression risk, symptoms and potential treatment-related considerations.
The study’s contribution is not simply that Livdelzi reduced a laboratory measurement. It provides randomised evidence in a population where the balance between initiating second-line treatment and continuing observation has historically been less clearly informed by pivotal clinical data.
How do the 2026 AASLD and AGA guidelines change the interpretation of IDEAL?
The IDEAL results arrive shortly after the American Association for the Study of Liver Diseases and the American Gastroenterological Association published updated clinical practice guidance for primary biliary cholangitis.
Announced on 22 October 2026, the joint guidance addresses the changing treatment landscape, including the use of newer peroxisome proliferator-activated receptor agonists as second-line options.
The guidance identifies ursodeoxycholic acid as the foundational first-line treatment and supports consideration of additional therapy when response is inadequate or the medicine is not tolerated.
Importantly, it also recognises normalisation of alkaline phosphatase as an ideal biochemical treatment goal when achievable, while emphasising the need to consider an individual’s disease severity and prognosis.
This development provides a timely context for IDEAL. The study demonstrates that a substantial proportion of patients with alkaline phosphatase levels between normal and 1.67 times normal can achieve the more demanding composite normalisation endpoint with seladelpar.
However, the guidelines do not establish a universal requirement for second-line therapy whenever alkaline phosphatase remains slightly elevated. The decision must account for the complete clinical picture and the strength of evidence supporting treatment.
The guideline recommendations for peroxisome proliferator-activated receptor agonists are conditional, reflecting the available evidence and remaining uncertainties.
Patients with greater liver stiffness or other indicators of progression risk may present different treatment considerations from patients with relatively stable disease and minimal biochemical abnormalities.
IDEAL strengthens the evidence concerning biochemical response but does not independently resolve how treatment should be prioritised across every risk group.
For hepatologists, the clinical importance lies in combining more ambitious biochemical targets with appropriate individual risk assessment. The results may contribute to a more nuanced approach to second-line treatment, particularly where the previous evidence base was concentrated among patients with more pronounced abnormalities.
What is the difference between Livdelzi’s current FDA approval and the new IDEAL evidence?
Livdelzi received FDA accelerated approval on 14 August 2024 for the treatment of primary biliary cholangitis in adults with an inadequate response to ursodeoxycholic acid, when used in combination with that treatment, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.
The medicine is an oral peroxisome proliferator-activated receptor delta agonist administered at a recommended dose of 10 mg once daily.
The accelerated approval was based on evidence that seladelpar reduces alkaline phosphatase, a biomarker associated with disease activity and prognosis in PBC.
The FDA-approved indication does not establish that Livdelzi has demonstrated improved survival or prevention of liver decompensation events. Continued approval may depend on verification and description of clinical benefit through appropriate confirmatory evidence.
The IDEAL study provides additional randomised evidence in a patient population with lower baseline alkaline phosphatase values than those typically included in previous pivotal studies.
However, the November findings are not a regulatory decision. Gilead Sciences has said it intends to engage with global regulatory authorities to discuss the results and their implications.
The company has not announced a new FDA approval, a revised United States prescribing indication or a completed regulatory label expansion based on IDEAL.
This distinction is important because clinical evidence can support treatment discussions and future regulatory considerations without immediately changing the legal basis on which a medicine is marketed.
The existing Livdelzi label already describes treatment in adults with inadequate response or intolerance to ursodeoxycholic acid. It does not define eligibility solely through the 1.67-times-normal threshold used in many earlier clinical trials.
Consequently, IDEAL should not automatically be described as establishing an entirely new FDA-approved patient population. Its principal contribution is strengthening the clinical evidence available for patients with less pronounced biochemical abnormalities.
Gilead’s regulatory discussions may clarify whether additional information could be incorporated into prescribing materials or support other jurisdiction-specific decisions.
Does alkaline phosphatase normalisation establish that Livdelzi prevents liver failure?
Alkaline phosphatase is an important biochemical marker in primary biliary cholangitis because elevated levels have been associated with an increased risk of disease progression.
Achieving normalisation may therefore indicate a more favourable biochemical response to treatment. However, a biomarker associated with prognosis is not equivalent to a directly measured clinical outcome.
The IDEAL primary endpoint assessed laboratory measurements rather than events such as liver transplantation, hepatic decompensation or death.
The study’s 52-week duration also limits its ability to establish effects on complications that may develop over several years.
A treatment can produce a substantial biochemical improvement without the available trial demonstrating the magnitude of its effect on long-term clinical events.
This is particularly important in a condition where disease progression can be slow and clinical outcomes may require extended follow-up across large patient populations.
The accelerated approval framework recognises the potential value of surrogate endpoints while requiring further evidence to verify clinical benefit when applicable.
For Livdelzi, the distinction between biochemical efficacy and long-term outcomes remains relevant even after the positive IDEAL findings.
Gilead has also reported longer-term observations from its broader seladelpar programme, including participants followed for up to five years in the ASSURE study.
Such evidence may provide useful information about sustained biochemical response and treatment tolerability. However, open-label extension data cannot automatically establish the same causal conclusions as a randomised clinical outcomes trial.
The strongest assessment of long-term clinical benefit will require appropriately designed studies examining relevant outcomes, alongside continued evaluation of the relationship between alkaline phosphatase response and disease progression.
IDEAL therefore strengthens an important part of the evidence package without resolving every question concerning the long-term benefit-risk balance.
What does IDEAL establish about Livdelzi’s safety in patients with milder biochemical abnormalities?
Gilead Sciences reported that the safety profile observed in IDEAL was consistent with findings from earlier Livdelzi studies, with no new safety concerns identified during the disclosed follow-up.
The overall incidence of adverse events was described as generally similar between the treatment and placebo groups.
Serious adverse events occurred in 3.1% of Livdelzi recipients and 12.9% of placebo recipients. According to the company, none of the reported serious adverse events was considered related to the assigned trial drug.
The numerical difference should be interpreted cautiously because the study included only 65 patients in the active-treatment group and 31 in the placebo group.
The trial was not designed to establish that Livdelzi reduces serious adverse events compared with placebo. A small number of events can produce substantial percentage differences in a relatively limited population.
The absence of newly identified safety concerns also does not eliminate established risks described in Livdelzi’s prescribing information.
The approved United States label includes warnings concerning fractures, liver test abnormalities and biliary obstruction. It also states that use is not recommended in patients who have or develop decompensated cirrhosis.
In the clinical programme supporting the original approval, fractures were reported in 4% of Livdelzi-treated patients compared with none receiving placebo.
The prescribing information also describes dose-related liver enzyme elevations observed at doses higher than the recommended therapeutic regimen. Appropriate liver function monitoring remains an important consideration under the approved label.
These established safety issues are especially relevant when considering treatment in patients with relatively modest biochemical abnormalities. The expected benefit of additional treatment must be evaluated against the potential burden of adverse effects and the requirements of ongoing monitoring.
The IDEAL results provide reassurance concerning the observed safety profile over 52 weeks, but longer-term evidence and broader clinical experience will remain important.
How does Livdelzi compare with competing second-line PBC treatments?
The treatment landscape for primary biliary cholangitis has expanded with the introduction of newer peroxisome proliferator-activated receptor agonists and other therapeutic approaches.
Livdelzi competes with alternatives including Ipsen’s Iqirvo (elafibranor), which also received accelerated FDA approval for adults with an inadequate response to or intolerance of ursodeoxycholic acid.
Both products have demonstrated biochemical treatment effects in their respective clinical programmes, although the trials were not designed as direct head-to-head comparisons.
The IDEAL findings add evidence for seladelpar in patients with baseline alkaline phosphatase values below the threshold traditionally used in many pivotal second-line studies.
However, the response rates reported in IDEAL should not be compared directly with percentages from trials enrolling patients with substantially higher baseline alkaline phosphatase or different clinical characteristics.
The probability of achieving a normal laboratory value can depend partly on the starting level. A patient beginning treatment just above the upper limit of normal has a different biochemical distance to cover from someone with markedly elevated measurements.
Differences in endpoint definitions also complicate comparisons. A composite requiring normal alkaline phosphatase and a minimum percentage reduction is not interchangeable with an endpoint permitting higher final alkaline phosphatase values or incorporating bilirubin criteria.
For clinicians, treatment selection may also involve symptoms, prior treatment response, comorbidities, safety considerations and patient preferences.
Livdelzi’s broader clinical programme includes evidence concerning pruritus, a common and sometimes debilitating symptom of PBC. However, the November IDEAL announcement focuses principally on biochemical normalisation rather than reporting a new comparative pruritus result.
Gilead will therefore need to position the findings within its complete evidence package rather than treating the study as proof of superiority over competing second-line therapies.
What do Livdelzi’s latest sales reveal about Gilead Sciences’ commercial opportunity?
Livdelzi is already contributing to Gilead Sciences’ liver disease business, with sales increasing substantially as the medicine gains commercial traction.
In the third quarter of 2026, Livdelzi generated US$203 million in global sales, compared with US$105 million in the corresponding period of 2025.
United States sales reached US$176 million, while European sales totalled US$26 million and other international markets contributed approximately US$1 million.
For the first nine months of 2026, global Livdelzi revenue reached US$503 million, compared with US$223 million during the same period of 2025.
These figures demonstrate meaningful commercial growth since the medicine’s original United States approval, although revenue expansion can reflect several factors, including treatment adoption, geographic availability, pricing and the maturation of commercial operations.
Gilead Sciences’ broader liver disease portfolio generated US$927 million during the third quarter, increasing 13% year on year. The company attributed part of that growth to stronger demand for Livdelzi.
The positive IDEAL results could strengthen the product’s clinical positioning, particularly among specialists managing patients with persistent but relatively modest alkaline phosphatase elevations.
However, an expanded evidence base does not automatically translate into an equivalent increase in prescriptions. Treatment decisions depend on individual clinical characteristics, payer policies, physician confidence and the economic implications of adding another medicine.
The size of the potential patient population must also be interpreted carefully. Gilead estimates that approximately 130,000 Americans are living with primary biliary cholangitis, but that figure does not represent the number of patients eligible for Livdelzi or likely to initiate treatment.
Some patients respond adequately to first-line therapy, while others may have contraindications, advanced disease or circumstances affecting treatment selection.
The incremental commercial contribution from IDEAL will depend on whether its findings influence treatment patterns in the narrower population studied.
For Gilead, the results provide an opportunity to support its existing PBC franchise through stronger clinical evidence rather than requiring the introduction of an entirely new commercial product.
How should Gilead Sciences investors interpret the IDEAL findings alongside third-quarter earnings?
Gilead Sciences reported third-quarter 2026 product sales of approximately US$8.3 billion, increasing 13% from the corresponding period of 2025.
The company’s HIV portfolio remained its largest revenue contributor, with quarterly HIV product sales increasing 18% to approximately US$6.2 billion.
Livdelzi’s US$203 million quarterly contribution is therefore relatively small compared with the scale of Gilead’s overall business, although its year-on-year growth provides evidence of expanding demand in the liver disease franchise.
The company also increased its full-year 2026 product sales guidance to US$31 billion to US$31.3 billion, reflecting broader portfolio performance.
Gilead shares closed at US$167.60 on 5 November, falling 3.94% during the session after closing at US$174.48 on 4 November.
The stock remained approximately 16% above its 6 October closing price, illustrating a positive one-month trend despite the sharp daily decline.
Its reported 52-week range was approximately US$116.88 to US$176.58, indicating that the shares had approached the upper end of their annual trading range before retreating.
The November IDEAL announcement alone does not explain the broader share-price movement. Gilead’s valuation reflects multiple businesses, earnings expectations, pipeline developments, acquisitions and capital allocation decisions.
The relevance of IDEAL is best understood as a clinical and commercial strengthening of an existing approved product. A positive biochemical result may help support continued uptake, but it is unlikely to determine the entire company’s investment outlook independently.
Investors will also need to consider the costs associated with additional clinical development, regulatory engagement and the continuing requirement to verify long-term benefit where applicable.
The most meaningful financial measure will be whether Livdelzi maintains revenue growth while Gilead expands its evidence base and secures appropriate access across additional markets.
What must Gilead Sciences establish before IDEAL changes routine PBC management?
The next important milestone is presentation of the full IDEAL results at the American Association for the Study of Liver Diseases’ Liver Meeting in Denver.
The study is scheduled for an oral presentation on 8 November 2026, with its findings also accepted for forthcoming publication in the Journal of Hepatology.
Peer-reviewed publication should provide additional information concerning baseline patient characteristics, statistical methodology, endpoint analyses and safety findings.
These details will be important for determining how the results apply to different patients with persistent alkaline phosphatase elevation.
Gilead Sciences also intends to discuss the findings with global regulatory authorities. Those discussions may clarify whether additional clinical evidence can support changes to prescribing information or other regulatory considerations.
However, the results should not be interpreted as a guarantee of a future label revision or expanded reimbursement.
The 2026 AASLD and AGA guidance already recognises alkaline phosphatase normalisation as an ideal goal when achievable and supports individualised second-line treatment decisions.
IDEAL provides randomised evidence that seladelpar can substantially increase the proportion of patients reaching a rigorous biochemical normalisation endpoint even when baseline alkaline phosphatase levels are below 1.67 times normal.
The remaining clinical challenge is determining which patients derive sufficient benefit from additional treatment to justify its risks, monitoring requirements and costs.
For Gilead Sciences, the trial strengthens a commercially growing PBC treatment at a time when clinical expectations are shifting towards more ambitious biochemical control.
Its longer-term value will depend on whether these findings can be integrated into evidence-based treatment decisions, supported by appropriate regulatory and reimbursement arrangements, and complemented by research establishing how sustained biochemical improvement relates to clinically meaningful liver outcomes.
